Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical company GW Pharma's Italian partner Almirall has rolled out Sativex in Italy, which can be used as a prescription medicine to treat moderate to severe spasticity in Multiple Sclerosis (MS) patients.
Subscribe to our email newsletter
Following approval for full marketing authorization from the Italian health authorities in May this year, the company introduced the medicine at reimbursed price, which is same as in Spain.
GW chief executive officer Justin Gover said that the launch of Sativex in Italy is an important step in the commercialization of the new medicine.
He further said that 21 countries have already approved Sativex for use in the treatment of MS spasticity, and the company is completing regulatory submissions in nine more nations.
Having two primary active components, THC (delta-9-tetrahidrocannabinol) and CBD (cannabidiol), the new medicine is administered as an oromucosal spray and contains cannabinoids which are extracted from the cannabis sativa plant.
A study has revealed that nearly 75% of MS patients suffer from spasticity in Italy, and clinical evidence has proved that Sativex improves quality of life and to greater patient independence from the help of their relatives and care-givers.